{
    "root": "34f352d5-bdca-df12-e063-6294a90a54bd",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Atovaquone",
    "value": "20250512",
    "ingredients": [
        {
            "name": "BENZYL ALCOHOL",
            "code": "LKG8494WBH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17987"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        },
        {
            "name": "POLOXAMER 188",
            "code": "LQA7B6G8JG",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32026"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "SACCHARIN SODIUM",
            "code": "SB8ZUX40TY",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32112"
        },
        {
            "name": "ATOVAQUONE",
            "code": "Y883P1Z2LT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_575568"
        }
    ],
    "indications": {
        "text": "atovaquone oral suspension quinone antimicrobial indicated : \u2022 prevention pneumocystis jirovecii pneumonia ( pcp ) adults adolescents aged 13 years older tolerate trimethoprim-sulfamethoxazole ( tmp-smx ) . ( 1.1 ) \u2022treatment mild-to-moderate pcp adults adolescents aged 13 years older tolerate tmp-smx . ( 1.2 ) limitations ( 1.3 ) : \u2022 treatment severe pcp ( alveolar arterial oxygen diffusion gradient [ ( a-a ) 2 ] > 45 mm hg ) atovaquone oral suspension studied . \u2022 efficacy atovaquone oral suspension subjects failing therapy tmp-smx also studied .",
        "doid_entities": [
            {
                "text": "pneumocystis jirovecii pneumonia (DOID:11339)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11339"
            },
            {
                "text": "pneumonia (DOID:552)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_552"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 prevention pcp : 1,500 mg ( 10 ml ) daily food ( 2.1 ) \u2022 treatment pcp : 750 mg ( 5 ml ) twice daily food 21 days ( 2.2 ) \u2022 supplied bottles : shake bottle gently . ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "atovaquone oral suspension , usp yellow homogenous suspension containing 750 mg atovaquone usp per 5 ml . \u2022 bottle 210 ml child-resistant cap ( ndc 31722-629-21 ) . store 15\u00b0 25\u00b0c ( 59\u00b0 77\u00b0f ) . freeze . dispense tight container defined usp .",
    "adverseReactions": "atovaquone oral suspension contraindicated patients develop history hypersensitivity ( e.g . , angioedema , bronchospasm , throat tightness , urticaria ) atovaquone components atovaquone oral suspension .",
    "indications_original": "Atovaquone oral suspension is a quinone antimicrobial drug indicated for: \u2022\u00a0Prevention of Pneumocystis\u00a0jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). ( 1.1) \u2022Treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX . (1.2) Limitations of Use (1.3): \u2022\u00a0 Treatment of severe PCP (alveolar arterial oxygen diffusion gradient\u00a0 [(A-a)DO 2 ] >45 mm Hg) with atovaquone oral\u00a0suspension has not been studied. \u2022\u00a0 The efficacy of atovaquone oral suspension in subjects who are failing therapy with TMP-SMX has also not been studied.",
    "contraindications_original": "\u2022\u00a0Prevention of PCP: 1,500 mg (10 mL) once daily with food (2.1) \u2022\u00a0Treatment of PCP: 750 mg (5 mL) twice daily with food for 21 days (2.2) \u2022\u00a0Supplied in\u00a0Bottles:\u00a0Shake bottle gently before use. (2.3)",
    "warningsAndPrecautions_original": "Atovaquone oral suspension, USP is a yellow homogenous suspension containing 750 mg atovaquone USP\u00a0per 5 mL. \n    \u2022\u00a0Bottle of 210 mL with child-resistant cap (NDC 31722-629-21). Store at 15\u00b0 to 25\u00b0C (59\u00b0 to 77\u00b0F).\n \n  Do not freeze. Dispense in tight container as defined in USP.",
    "adverseReactions_original": "Atovaquone oral suspension is contraindicated in patients who develop or have a history of hypersensitivity reactions (e.g., angioedema, bronchospasm, throat tightness, urticaria) to atovaquone or any of the components of atovaquone oral suspension.",
    "drug": [
        {
            "name": "Atovaquone",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_575568"
        }
    ]
}